Management of Heart Failure in Primary Care and the use of Forxiga (dapagliflozin) - Questions and Answers

AstraZeneca have provided financial support for this blended learning series and have had no involvement in the content or speaker selection

Dr Jim Moore and Dr Derek Connolly broadcasted a live webinar on 20th May on behalf of the PCCS.

They focused on key diagnostic assessments that would be expected in a primary care setting and discussed the available treatment options for HFrEF.

They examined when dapagliflozin would be suitable based on its new licenced indication and provided a narrative on the Cardiovascular Outcome Trials (CVOT) and the development of dapagliflozin in the treatment of HFrEF.

They also reviewed the NICE guidance for dapagliflozin in HFrEF including commenting on which patients it would be appropriate to treat with dapagliflozin.

The Question and Answer sheet contains delegate questions which were not answered during the live webinar due to time constraints.

The entire webinar including additional questions that were answered and discussed during the session can be viewed here:

https://pccsuk.org/2020/en/page/az-blended-webinar

PCCS Observer Council Member, Consultant Interventional Cardiologist and Director of Research & Development, Birmingham City Hospital

Prof Derek Connolly is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham UK.

He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge.

He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine.

He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes.